News

Here is how we scale up our production. In collaboration with Zühlke Engineering AG

Fabienne Hartmann-Fritsch still feels most at home in the lab, even though she now spends more time in front of her PC than inspecting Petri dishes. In 2017, the biologist founded the spin-off CUTISS together with four other UZH scientists. Once clinical trials are complete, the spin-off plans to roll out personalized skin tissue therapy on the market – in other words, customized human skin grown in the lab. During her doctoral studies at the University Children’s Hospital Zurich, Hartmann-Fritsch started specializing in planning and executing clinical research projects involving humans and dealing with the legal framework. The transition from pure research to (communications) management was an easy one for her. “It’s immensely gratifying to now be able to apply the results of years’ worth of lab work,” she says. The innovative product that is supposed to increase the quality of life of people suffering from skin defects is called denovoSkin. In the second trial phase, the researchers will now test the safety and effectiveness of the skin replacement in various clinics. For Hartmann-Fritsch, this means extensive talks with medics, sponsors and the authorities.

Text: Alice Werner
Picture: Frank Brüderlin

We’re proud to announce that we have been selected as @hellotmrc Global Finalists, from the world-renowned #HTChallenge! From over 5000 applications, we are one of the seven ‘Medical Biotech’ finalists. Come and see us pitch to win at the #HTSummit in Paris, March 12-13th 2020!

CUTISS AG is present with a booth at the EBA 2019 in Helsinki. Further information about the congress, also for the upcoming events of the EBA can be found under “Learn more”

Swiss researchers want to develop the first-ever automated machine to bioengineer personalised skin grafts for therapy. The denovoCast project, a collaboration between life science start-up Cutiss AG and CSEM, has been awarded a grant of more than CHF 800’000 by Innosuisse.

CUTISS reaches milestone: publication of Phase I of the Clinical Studies of denovoSkin!

The denovoFix transport box was developed by Astrid Welti as a Bachelor Thesis in cooperation with the Zürcher Hochschule der Künste (ZHdK).

CUTISS AG receives SME Instrument Grant for 2.5 Million Euros to automate.

Read more about this on startupticker.ch –

Cutiss, SamanTree Medical and RqMicro have been selected for the SME Instrument. The startups will be supported in the Phase 2 of the SMI Instrument, with up to €2.5 million in funding.

CUTISS AG is among the 10 Swiss Venture Leaders that will fly to Boston!

Ten new startups have been selected to become the next Venture Leaders Life Sciences 2018. Chosen from among the most promising Life Sciences startups in Switzerland, the team will embark on a fully packed one-week roadshow in Boston. Meet the team at the Startup Champions Seed Night event on May 2nd.
Following in the footsteps of fellow alumni like Insphero or Covagen, the Venture Leaders Life Sciences 2018 team members will join the 17th edition for a deep dive into Boston’s Life Sciences industry between May 27th and June 3rd. For an intense week, the newly constituted Swiss National Startup Team will have the opportunity to build a solid network through exchanges with local peers, meetings with key Medtech and Biotech industry leaders, and pitches in front of investors, all in order to boost their global expansion ambitions. The Boston region is considered to be one of the major Life Sciences hub worldwide, representing an ideal environment for the Swiss-based startups to get exposure and visibility as well showcasing Switzerland as a breeding ground for innovation in Life Sciences.

University of Zurich receives Swissmedic approval to commence phase II denovoSkin™ trial for reconstructive surgery in adults and children.